DYSPEPSIA GENERATION

We have seen the future, and it sucks.

Drug Candidate Designed at Scripps Research Institute Leads to Improved Endurance

4th October 2013

Read it.

The drug candidate, SR9009, is one of a pair of compounds developed in the laboratory of TSRI Professor Thomas Burris and described in a March 2012 issue of the journal Nature as reducing obesity in animal models. The compounds affect the core biological clock, which synchronizes the rhythm of the body’s activity with the 24-hour cycle of day and night.

Comments are closed.